Romosozumab

1. Romosozumab increases alveolar bone mineral density in humans.

   Humansosteoporosisfemales

   Alveolar Bone Mineral Density Correlates with Lumbar Spine Bone Mineral Density During Romosozumab Therapy: A Prospective Observational Study In Osteoporosis · Research Square · 25 Sep 2026 · Preprint

Alveolar bone mineral density →

1. Romosozumab decreases TRACP-5b in humans (-32.1% vs. -33.1%).

   Humansosteoporosissubcutaneous210 mg monthly12 months

   Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan · Calcified tissue international · 25 Sep 2026

TRACP-5b →

1. Romosozumab decreases P1NP in humans (median -16.4% vs. -19.6%).

   Humansosteoporosissubcutaneous210 mg monthly12 months

   Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan · Calcified tissue international · 25 Sep 2026

P1NP →

1. Romosozumab increases lumbar spine bone mineral density in humans (+10.9% [IQR 6.2 to 20.0]).

   Humansosteoporosissubcutaneous210 mg monthly12 monthsn = 69

   Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan · Calcified tissue international · 25 Sep 2026